Costa Rica Medical Device Legal Framework: Five Layers of Sources

1. Key takeaways

The legal sources for medical devices in Costa Rica are arranged in five layers: the Constitution, statutes, administrative decrees (the vehicle of the main regulation), transitional provisions, and the portal and its forms. The current main regulation is RTCR 505:2022, Equipo y Material Biomédico. Clasificación, Registro, Importación, Etiquetado, Publicidad, Vigilancia y Control, approved by Decreto Ejecutivo N° 43902-S (30 November 2022) under internal reference MS-AJ-CB-412-2022, comprising 25 articles plus Annex A and Annex B; Article 7 of the approving decree provides that the regulation enters into force six months after its publication. In 2024 a further amending decree (internal reference MS-AJ-CB-200-2024) modified four of its provisions and one transitional provision.

• Five layers: Constitution, statutes, administrative decrees, transitional provisions, portal and forms.
• RTCR 505:2022 is approved by Decreto Ejecutivo N° 43902-S, internal reference MS-AJ-CB-412-2022.
• Article 7 of the approving decree sets entry into force at six months after publication.
• The 2024 amending decree (MS-AJ-CB-200-2024) modified provisions 4.7, 10.20, 17.3 and 18.11.4 and Transitional Provision III.
• DE 34482-S, the former regulation, was partially repealed, not abolished in its entirety.

2. Legal basis

The table below maps the five layers of legal sources, the instruments that compose them, their dates and the points that matter for device compliance in Costa Rica.

3. Expert insights

Insight one: the enabling chain of the main regulation combines health statutes and administrative-procedure statutes, and this determines how often it is revised. The opening recital of the approving decree lists as enabling bases both Ley 5395 (the General Health Law), Articles 1, 2, 4, 7, 49 and 142–145, and Ley 8220 (the statute on the protection of administrative procedures) and Ley 8274 (the National Quality System Law). Because the legislative purpose of Ley 8220 is to restrain the excessive addition of administrative formalities, the main regulation had to pass ex-ante better-regulation control (Article 12 bis of DE 37045-MP-MEIC) and public consultation. Article 7 of the CONSIDERANDO of the 2024 amending decree expressly records that this amendment was published for public consultation on the Ministry of Health website for 10 working days from 12 December 2023. This paper trail shows that Costa Rican device regulation is legislation of the continuously fine-tuned kind, and companies should treat it as a dynamic document requiring periodic review, not as a static rule set that can be read once.

Insight two: the entry-into-force rule is six months after publication, not immediate effect upon publication. The original wording of Article 7 of the approving decree is “Rige 6 meses después de su publicación”. The official text obtained for this verification does not record the issue number or date of publication in the official gazette (La Gaceta), so this volume does not state a specific calendar date of entry into force; the industry-circulated claim of entry into force on 9 September 2023 is a practical estimate and must be re-checked against the official gazette. By contrast, Article 3 of the 2024 amending decree uses “Rige a partir de su publicación en el diario oficial La Gaceta”, that is, effect upon publication. The two decrees use different entry-into-force mechanisms, which is precisely why the amendment needed immediate effect while the main regulation needed a preparation period.

Insight three: the former regulation was partially repealed, not abolished in its entirety, and surviving provisions remain binding. Article 4 of the approving decree precisely lists the scope of repeal: Articles 1–18, 20, 22 and 24–30 of DE 34482-S, together with procedure DAJ-RM-1151-08. Under this list, Articles 19, 21 and 23 are not within the scope of repeal. At the same time, Article 6 replaces, as from the entry into force of RTCR 505:2022, all normative references pointing to DE 34482-S with references to the new regulation, including existing equivalence-recognition documents for registration systems. This approach avoided invalidating legacy recognition documents, but it also means that whenever a pre-2023 Costa Rican device document cites DE 34482-S, a reference substitution must be applied under Article 6.

Insight four: the four transitional provisions each address one category of legacy issues, and two of them are still operative. Transitional Provision I suspends the GMP certificate obligation until the GMP regulation for national EMB is issued; Transitional Provision IV requires the Ministry of Health to issue that regulation within 12 months of entry into force; Transitional Provision II keeps the approved intended uses of legacy registrations valid until the original registration expires; Transitional Provision III opened a window for legacy registrations to submit product labelling, extended in 2024 from 6 months to 18 months. Together these four provisions form a complete new-versus-old transition design and are the sole basis for judging the validity of legacy certificates.

4. Practical recommendations

• Maintain a legal-source register: record the full name, number, date and current status of each instrument across the five layers of the table above, and re-verify it every six months.
• When reviewing any pre-2023 Costa Rican device document, first apply the reference substitution under Article 6 of the approving decree, then assess whether the provision remains valid.
• For matters touching the surviving provisions of DE 34482-S (Articles 19, 21 and 23), confirm the current validity of each provision before citing it; do not apply the former regulation wholesale.
• State the effective date uniformly as “six months after publication in the official gazette”, and do not write a specific calendar date in external documents unless it has been verified against the gazette.
• If product labelling of a legacy registration is not in the dossier, plan the submission within the 18-month window of Transitional Provision III and retain the submission receipt.

5. Verification checklist

• □ Record the full title of the main regulation, the approving decree number and the internal reference MS-AJ-CB-412-2022
• □ Record the Article 7 entry-into-force rule (6 months after publication); do not write a calendar date not verified against the gazette
• □ Record the 2024 amending decree internal reference MS-AJ-CB-200-2024 and its four modifications
• □ Check the repealed-provision list of DE 34482-S (Articles 1–18, 20, 22, 24–30) and the surviving provisions
• □ Complete the reference substitution for legacy documents under Article 6
• □ Check the applicability status of Transitional Provisions I–IV one by one
• □ Record the public-consultation paper trail (10 working days from 2023-12-12)

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Costa Rican market. Our team manages Ministry of Health (Ministerio de Salud) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com